Skip to main content

Table 2 Outcomes of macular HEs following IVR therapy

From: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

  One month Three month P-value
n 288 288  
2-grade reduction 69 (23.9%) 155 (53.8%) 0.000***
No change in the area 143 (49.6%) 90 (31.2%) 0.001**
2-grade enlargement 76 (26.3%) 43 (14.9%) 0.000***
  1. IVR Intravitreal injections of ranibizumab. **, p < 0.01; ***, p < 0.001, compared one month and three month data